期刊
MAYO CLINIC PROCEEDINGS
卷 96, 期 5, 页码 1262-1275出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2021.02.008
关键词
-
资金
- National Heart, Lung, and Blood Institute [R01 HL059842, 5R35HL139854]
- National Institute of Diabetes and Digestive and Kidney Diseases [5T32DK07352]
- Natural Sciences and Engineering Research Council of Canada [PDF-532926-2019]
- National Institutes of Health [1-F32-HL154320-01]
- National Institute of Allergy and Infectious Diseases [R21 AI145356, R21 AI152318, R01 AI1520789]
Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19. (c) 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据